Partially HLA-matched irradiated donor lymphcyte infusion alone resulted in 27% overall response rate (ORR) in advanced renal cell carcinoma without significant toxicities. In addition, high-dose interleukin-2 (IL-2)showed an ORR of 6-21% in metastatic melanoma or renal cell carcinoma with a durable response in patients who achieved complete remission. Therefore, irradiated donor lymphocyte infusion plus high-dose IL-2 might show a synergistic anti-tumor activity agaist relapsed or metastatic melanoma or renal cell carcinoma.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
9
Seoul National University Hospital
Seoul, South Korea
12-week modified immune-related response rate
Time frame: 12-week
6-week modified immune-related response rate
Time frame: 6-week
Overall response rate based on RECIST v1.1
Time frame: 6/12-week
Progression-free survival
Time frame: 6-month
Overall survival
Time frame: 1-year
Immune-related adverse events
Time frame: 12-week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.